conbercept
Trade name: Lumitin
Recombinant proteinexperimental
Clinical trial activity
40 trials · 25 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
18
Phase 3
8
Phase 4
10
Earliest trial started Aug 1, 2009 (NCT01242254)
Timeline
Indications
Approved for
Studied for
- Choroidal Neovascularization · Phase 2
- Corneal Neovascularization · Phase 1
- Diabetic Retinopathy · Phase 4
- Hemangioma · Early Phase 1
- Livedoid Vasculopathy · Phase 4
- Macular Degeneration · Phase 4
- Macular Edema · Phase 4
- Neovascularization, Pathologic · Phase 3
- Pharmacokinetics · Phase 2/Phase 3
- Receptors, Vascular Endothelial Growth Factor · Phase 4
- Resuscitation · Phase 3
- Retinal Diseases · Phase 4
- Retinal Vein Occlusion · Phase 3
- Retinoblastoma · Phase 2
- Shock, Septic · Phase 3
- Uveitis · Phase 2/Phase 3
- Vascular Endothelial Growth Factor A · Phase 2/Phase 3
- Wet Macular Degeneration · Phase 2
Mechanism of action
- Placenta growth factorINHIBITOR
PGF inhibitor
Soluble receptor decoy which has a high binding affinity to VEGF and a long half-life in vitreous.
All isoforms of VEGF-A, VEGF-B, VEGF-C, and PlGF.
- Vascular endothelial growth factor CINHIBITOR
VEGFC inhibitor
Soluble receptor decoy which has a high binding affinity to VEGF and a long half-life in vitreous.
All isoforms of VEGF-A, VEGF-B, VEGF-C, and PlGF.
- Vascular endothelial growth factor AINHIBITOR
VEGFA inhibitor
Soluble receptor decoy which has a high binding affinity to VEGF and a long half-life in vitreous.
All isoforms of VEGF-A, VEGF-B, VEGF-C, and PlGF.
- Vascular endothelial growth factor BINHIBITOR
VEGFB inhibitor
Soluble receptor decoy which has a high binding affinity to VEGF and a long half-life in vitreous.
All isoforms of VEGF-A, VEGF-B, VEGF-C, and PlGF.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2108313 ↗
Also known as
- conbercept
- conbercept
- conbercept
- conbercept
- kh902
- kh-902
- kh902 fusion protein
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07133438 | Phase 4 | Sep 1, 2025 | Chongqing Medical University |
| NCT06845163 | Phase 2 | Feb 8, 2025 | Alexandria University |
| NCT07144865 | N/A | Dec 1, 2024 | Tianjin Medical University |
| NCT06717412 | N/A | Nov 29, 2024 | Xijing Hospital |
| NCT06305143 | Phase 4 | Apr 1, 2024 | Jiao Tong University, Shanghai Eye Disease Prevention and Treatment Center |
| NCT05728476 | N/A | Nov 1, 2023 | Tianjin Medical University |
| NCT06122909 | Phase 3 | Jul 21, 2023 | Cairo University, Mansoura University |
| NCT05642793 | Phase 2 | Apr 1, 2022 | Peking University |
| NCT04990271 | Phase 2 | Jul 5, 2021 | Chengdu Kanghong Biotech Co.,Ltd., Jiao Tong University |
| NCT04782115 | Phase 2 | Mar 17, 2021 | RemeGen |
| NCT04627402 | N/A | Nov 12, 2020 | Sun Yat-Sen University |
| NCT04380974 | Phase 4 | Jun 30, 2020 | Fudan University, Jiao Tong University |
| NCT04296838 | Phase 2/Phase 3 (Phase 3) | Oct 12, 2019 | Beijing Bethune public welfare fund, Chinese Academy of Medical Sciences |
| NCT04215393 | Phase 1 | Jul 18, 2019 | Chengdu Kanghong Biotech Co.,Ltd. |
| NCT03971162 | N/A | Jun 1, 2019 | Sun Yat-Sen University |
| NCT03863535 | N/A | Jan 18, 2019 | Jiao Tong University, Shanghai Municipal Science and Technology Commission |
| NCT03630952 | Phase 3 | Sep 1, 2018 | Chengdu Kanghong Biotech Co.,Ltd. |
| NCT03577899 | Phase 3 | Jul 1, 2018 | Chengdu Kanghong Biotech Co.,Ltd. |
| NCT03571282 | Early Phase 1 (Phase 1) | Jun 6, 2018 | Sun Yat-Sen University |
| NCT03506750 | Phase 4 | Jun 3, 2017 | Nanjing Medical University |
Showing 20 of 40 trials
Page 1 / 2
Organizations
Research & Development (25)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chengdu Kanghong Biotech Co.,Ltd. | For profit | 15 | 15 | 4 | 2009 |
| Jiao Tong University | Academic/Hospital | 7 | 4 | 3 | 2010 |
| Sun Yat-Sen University | Academic/Hospital | 5 | 5 | 2 | 2014 |
| Tianjin Medical University | Academic/Hospital | 4 | 4 | 3 | 2016 |
| Chongqing Medical University | Academic/Hospital | 2 | 2 | 2 | 2016 |
| Fudan University | Academic/Hospital | 2 | 0 | 1 | 2016 |
| Peking University | Academic/Hospital | 2 | 1 | 1 | 2010 |
| People's Liberation Army of China | Government | 2 | 0 | 1 | 2009 |
| University of Wisconsin | Academic/Hospital | 2 | 0 | 1 | 2009 |
| Alexandria University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Beijing Bethune public welfare fund | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Beijing DMS Pharma Ltd. | For profit | 1 | 0 | 1 | 2010 |
| Cairo University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Mansoura University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Nanjing Medical University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Novartis | For profit | 1 | 1 | 1 | 2016 |
| RemeGen | For profit | 1 | 1 | 1 | 2021 |
| Shanghai Eye Disease Prevention and Treatment Center | Academic/Hospital | 1 | 1 | 1 | 2024 |
25 organizations
Page 1 / 2